Breastcancer.org Podcast

Dr. Luca Gianni, president of the Fondazione Michelangelo in Milan, discusses the results of the NeoTRIP trial, which looked to see if adding the immunotherapy medicine Tecentriq (chemical name: atezolizumab) to chemotherapy before surgery for triple-negative breast cancer with a high risk of recurrence could improve the time women lived without the cancer coming back. Running time: 7:17 Thank you for listening to the Breastcancer.org podcast. Please subscribe on iTunes, Stitcher, Spotify, TuneIn, or wherever you listen to podcasts. To share your thoughts about this or any episode, leave feedback on the podcast episode landing page on our website.